AA
VIRX

Addison Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Addison Advisors’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4
Closed -$1 – 886
2024
Q4 		$1 Hold
4
– – ﹤0.01% 839
2024
Q3 		$1 Hold
4
– – ﹤0.01% 835
2024
Q2 		$3 Hold
4
– – ﹤0.01% 774
2024
Q1 		$5 Hold
4
– – ﹤0.01% 698
2023
Q4 		$3 Hold
4
– – ﹤0.01% 702
2023
Q3 		$5 Hold
4
– – ﹤0.01% 678
2023
Q2 		$6 Hold
4
– – ﹤0.01% 628
2023
Q1 		$7 Hold
4
– – ﹤0.01% 627
2022
Q4 		$6 Hold
4
– – ﹤0.01% 785
2022
Q3 		$0 Hold
4
– – ﹤0.01% 785
2022
Q2 		$0 Hold
4
– – ﹤0.01% 792
2022
Q1 		$0 Hold
4
– – ﹤0.01% 802
2021
Q4 		$0 Hold
4
– – ﹤0.01% 729
2021
Q3 		$0 Hold
4
– – ﹤0.01% 463
2021
Q2 		$0 Buy
+4
New +$40 ﹤0.01% 410
2020
Q4 		$0 Buy
+5
New +$26 ﹤0.01% 387

Other funds holding VIRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Addison Advisors's VIRX Position: Q1 2025 in Review

Addison Advisors sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2025, closing a stake of 4 shares — an estimated $1 sold.

Addison Advisors first reported a position in VIRX in Q4 2020 and held it in 16 quarters. The position peaked at $7 in Q1 2023. 7 funds tracked by Wall St. Rank hold VIRX as of Q1 2025.

  • Addison Advisors reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Addison Advisors sold 4 Viracta Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $1.
  • Addison Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2020 and held it in 16 quarters.
  • Addison Advisors's Viracta Therapeutics, Inc. Common Stock position peaked at $7 in Q1 2023.
  • 7 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Addison Advisors's 13F filing for Q1 2025, filed 12 May 2025.